1. Home
  2. BMEA vs SOTK Comparison

BMEA vs SOTK Comparison

Compare BMEA & SOTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.27

Market Cap

91.1M

Sector

Health Care

ML Signal

HOLD

Logo Sono-Tek Corporation

SOTK

Sono-Tek Corporation

HOLD

Current Price

$5.30

Market Cap

73.7M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMEA
SOTK
Founded
2017
1975
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
91.1M
73.7M
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
BMEA
SOTK
Price
$1.27
$5.30
Analyst Decision
Strong Buy
Hold
Analyst Count
6
1
Target Price
$9.83
N/A
AVG Volume (30 Days)
566.6K
43.0K
Earning Date
05-12-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
69.19
37.50
EPS
N/A
0.05
Revenue
N/A
$20,909,315.00
Revenue This Year
N/A
$4.02
Revenue Next Year
N/A
$10.95
P/E Ratio
N/A
$108.40
Revenue Growth
N/A
1.97
52 Week Low
$0.87
$3.23
52 Week High
$2.99
$6.24

Technical Indicators

Market Signals
Indicator
BMEA
SOTK
Relative Strength Index (RSI) 47.54 53.18
Support Level $1.21 $4.69
Resistance Level $1.44 $5.79
Average True Range (ATR) 0.06 0.35
MACD -0.00 0.01
Stochastic Oscillator 58.14 52.53

Price Performance

Historical Comparison
BMEA
SOTK

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

About SOTK Sono-Tek Corporation

Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.

Share on Social Networks: